Kv9 is developing an autologous cancer vaccine that utilizes a unique method to break down tumor cells, exposing their components to stimulate a targeted immune response. This approach aims to provide a low-risk, affordable treatment option for the over two million dogs diagnosed with cancer annually in the U.S.
Funding
Funding not disclosed
Founders
Product
Problem
Over two million dogs are diagnosed with cancer annually in the U.S., and current treatment options are often high-risk, expensive, and difficult to access. Cancer is the leading cause of death in dogs.
Solution
Kv9 is developing an autologous cancer vaccine designed to stimulate a targeted immune response against tumor cells. The vaccine utilizes a novel method to break down a patient's own tumor cells, exposing their components to the immune system. This approach aims to provide a low-risk and more affordable treatment option compared to existing therapies, making it accessible to a wider range of veterinary clinics. By harnessing the body's own processing systems, Kv9 seeks to create a powerful and specific immune response to combat cancer in pets.
Target Audience
The primary target audience is veterinary clinics and pet owners seeking alternative and more accessible cancer treatment options for dogs.
Features
- Autologous vaccine using the patient's own tumor cells.
- Unique method for tumor cell breakdown to expose antigens.
- Stimulation of a targeted immune response against cancer cells.
- Designed to be a low-risk treatment option.
- Aims to be more affordable than current cancer treatments.
- Intended for availability at any veterinary clinic.